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Abstract We established stable human canalicular multispecific
organic anion transporter (cMOAT/MRP2) cDNA transfec-
tants, CHO/cMOAT from non-polarized Chinese hamster ovary
(CHO)-K1 and LLC/cMOAT from polarized pig kidney
epithelial LLC-PK1. Human cMOAT was mainly localized in
the plasma membrane of CHO/cMOAT and in the apical
membrane of LLC/cMOAT. The ATP-dependent uptake of
leukotriene C4 (LTC4) into CHO/cMOAT membrane vesicles
was enhanced compared with empty vector transfectants. Km
values in CHO/cMOAT membrane vesicles were 0.24 WM for
LTC4 and 175 WM for ATP. Drug sensitivity to vincristine and
cisplatin in human cMOAT cDNA transfectants decreased, but
not to etoposide. Cellular accumulation of vincristine and
cisplatin in human cMOAT cDNA transfectants decreased, but
not of etoposide. The uptake of LTC4 into CHO/cMOAT
membrane vesicles was inhibited by exogenous administration of
vincristine or cisplatin, but not that of etoposide. Moreover, this
inhibition was more enhanced in the presence of glutathione.
These consequences indicate that drug resistance to vincristine or
cisplatin appears to be modulated by human cMOAT through
transport of the agents, possibly in direct or indirect association
with glutathione.
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1. Introduction
Both P-glycoprotein (Pgp) and multidrug resistance protein
1 (MRP1) belong to the ATP binding cassette (ABC) trans-
porter superfamily, and mediate multidrug resistance through
altered membrane transport of various anticancer agents in
cancer cells [1^4]. Human canalicular multispeci¢c organic
anion transporter (cMOAT/MRP2) also belongs to the ABC
transporter superfamily and shows a 49% amino acid identity
to human MRP1 [5,6]. Rat [7] and rabbit [8] cMOAT trans-
port a GSH conjugate, leukotriene C4 (LTC4), which is a high
a⁄nity endogenous substrate for MRP1 [9^12]. This structur-
al and functional similarity between cMOAT and MRP1 sug-
gests that overexpression of cMOAT may confer multidrug
resistance. Human cMOAT is substantially overexpressed in
several cell lines, and human cMOAT levels correlate with
cisplatin resistance in a subset of resistant cell lines [5,6]. A
potent anticancer agent, cisplatin, which forms glutathione
(GSH) conjugates, is predicted to be e¥uxed through the
GS-X pump [13,14]. In our previous study, introduction of
the human cMOAT antisense cDNA into human hepatic can-
cer HepG2 cells overexpressing human cMOAT results in in-
creased sensitivity to cisplatin and vincristine, but not to eto-
poside [15]. In the human cMOAT antisense cDNA
transfectants, cellular accumulation of cisplatin and vincris-
tine increases, but cellular accumulation of etoposide does
not change [15]. Transport of another anticancer agent, vin-
blastine, is also altered in polarized Madin-Darby canine kid-
ney cells transfected with human cMOAT cDNA [16]. How-
ever, whether human cMOAT itself is involved in the
membrane transport of any speci¢c anticancer agent like
MRP1 or Pgp remains unclear.
In this study, we established stable human cMOAT cDNA
transfectants from non-polarized Chinese hamster ovary
(CHO)-K1 and polarized LLC-PK1 cells, and examined if
the drug sensitivity and cellular accumulation are altered in
the transfectants. We further examined if human cMOAT
transports LTC4 which is a substrate for MRP1 [9^12] by
using the membrane vesicles from human cMOAT cDNA
transfectants, and if human cMOAT modulates the membrane
transport of anticancer agents in association with GSH.
2. Materials and methods
2.1. Drugs and chemicals
Cisplatin was donated by Bristol-Myers Squibb K.K. (Kanagawa,
Japan). Vincristine was purchased from Sigma Chemical Co. (St.
Louis, MO, USA). Etoposide was obtained from Nippon Kayaku
Co. (Tokyo, Japan). Lipofectamine and geneticin (G418) were pur-
chased from Life Technologies, Inc. (Bethesda, MD, USA).
[14,15,19,20-3H(N)]-LTC4 was obtained from DuPont NEN (Boston,
MA, USA).
2.2. Construction of human cMOAT expression vector
Previously described cDNA overlapping clones (L3, AL28-33, 4-1,
1-1, AK1-8) [5] were reconstructed into a full-length cDNA, which
was inserted into the NotI site of the pCI-neo mammalian expression
vector (Promega).
2.3. Cell culture and transfection with human cMOAT expression
vector
CHO-K1 and LLC-PK1 cells were cultured in Eagle’s MEM (Nis-
sui, Tokyo) containing 10% newborn calf serum and Medium 199
(Nissui, Tokyo) containing 10% fetal bovine serum, respectively.
Transfection of human cMOAT expression vector was performed us-
ing lipofectamine according to the manufacturer’s protocol. The cells
were incubated in a selection medium containing 800 Wg/ml G418 for
3^4 weeks. The stable transfectants expressing human cMOAT were
selected using Western blot analysis among G418-resistant clones.
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2.4. Production of human cMOAT antibody
Antibody against human cMOAT was elicited by synthetic peptide
DYGLISSVEEIPEDAAS that corresponded to the unique amino
acid sequence at the linker region of human cMOAT (amino acids
884^900). The amino acid sequence of the linker region was unique
when we compared it with the amino acid sequences of the corre-
sponding regions of MRP1 and MRP3-MRP6. The human cMOAT
antibody was a⁄nity puri¢ed with the glutathione S-transferase hu-
man cMOAT fusion proteins. This antibody did not cross-react with
Pgp or MRP1 [15]. Double immuno£uorescence using this antibody
and anti-DPPIV antibody, and confocal laser scanning microscopy,
showed localization of human cMOAT in the canalicular membrane
domain of normal human hepatocytes but not in patients with Dubin-
Johnson syndrome [17].
2.5. Western blot analysis and indirect immuno£uorescence
An immunoblot analysis of human cMOAT was made as described
by Koike et al. [15]. Aliquots of whole cell lysates (200 Wg) were
electrophoresed on 6% SDS-polyacrylamide gels and were analyzed
by immunoblotting with human cMOAT antibody. Protein-antibody
interaction was detected using the enhanced chemiluminescence tech-
nique.
Indirect immuno£uorescence analysis was performed as described
by Koike et al. [18].
2.6. Membrane vesicle preparation and [3H]LTC4 uptake in membrane
vesicles
Membrane vesicles were prepared by the nitrogen cavitation meth-
od as described by Cornwell et al. [19] from CHO/CMV and CHO/
cMOAT-1 cells.
LTC4 uptake in membrane vesicles was measured by a rapid ¢ltra-
tion technique essentially as described by Ishikawa et al. [13,20].
Brie£y, the standard incubation medium contained membrane vesicles
(50 Wg of protein), 1.368 nM [3H]LTC4, 0.25 M sucrose, 10 mM Tris-
HCl, pH 7.4, 10 mM MgCl2, 4 mM ATP, 10 mM phosphocreatine
and 100 Wg/ml creatine phosphokinase in a ¢nal volume of 50 Wl. The
reaction was carried out at 37‡C. The samples were passed through
Millipore ¢lters (GVWP, 0.22 Wm pore size) under a light vacuum to
measure the trapped [3H]LTC4 in the vesicles. The ¢lters were washed
and placed in scintillation £uid. The level of radioactivity was meas-
ured using a liquid scintillation counter. ATP-dependent accumula-
tion was calculated from the di¡erence in the radioactivity incorpo-
rated into the vesicles in the presence or absence of 4 mM ATP.
2.7. Chemosensitivity and cellular accumulation of vincristine, cisplatin
and etoposide
A colony formation assay was made as described by Koike et al.
[15]. The 50% lethal dose (IC50) for each cell line was calculated from
the dose-response curve. The relative resistance of human cMOAT
cDNA transfectants was determined by dividing the IC50 value for
each transfectant by that of the empty vector transfectant. The accu-
mulation of etoposide, vincristine and cisplatin was determined as
described by Koike et al. [15].
3. Results
We established cell lines overexpressing human cMOAT by
introducing the human cMOAT expression vector into non-
polarized CHO-K1 and polarized LLC-PK1 cells. Western
blot analysis with human cMOAT antibody showed the pres-
ence of human cMOAT of molecular weight 190^200 kDa in
the human hepatic cancer HepG2 cells. Human cMOAT
cDNA transfectants (CHO/cMOAT-1, 2 and LLC/cMOAT-
1, 2 cells) expressed human cMOAT of molecular weight of
180^190 kDa, while cells transfected with empty vector alone
(CHO/CMV and LLC/CMV cells) and parental cells (CHO-
K1 and LLC-PK1 cells) did not express human cMOAT (Fig.
1).
The cellular distribution of human cMOAT was determined
by indirect immuno£uorescence with the human cMOAT
antibody (Fig. 2). The photomicrographs of the horizontal
section of CHO/CMV (Fig. 2A), CHO/cMOAT-1 (Fig. 2B)
and CHO/cMOAT-2 (Fig. 2C) cells show that the human
cMOAT expression was observed in human cMOAT cDNA
transfectants, and that human cMOAT was mainly localized
in the plasma membrane. The photomicrographs of the top
views of LLC/CMV (Fig. 2D), LLC/cMOAT-1 (Fig. 2E) and
LLC/cMOAT-2 (Fig. 2F) cells show that the human cMOAT
expression was also observed in human cMOAT cDNA trans-
fectants. The photomicrograph of the vertical section of LLC/
cMOAT-2 cell layer shows that the human cMOAT expres-
sion was mainly observed in the apical plasma membrane
(Fig. 2G).
By using the membrane vesicles of human cMOAT cDNA
transfectants, we examined if human cMOAT also transports
LTC4 like MRP1. Fig. 3A shows the time course of [3H]LTC4
uptake into membrane vesicles from CHO/CMV and CHO/
cMOAT-1 cells in the absence or presence of ATP. We found
a dramatic di¡erence in LTC4 uptake between CHO/CMV
and CHO/cMOAT-1 vesicles when incubated in the presence
of ATP. By contrast, any apparent LTC4 uptake could not be
observed between CHO/CMV and CHO/cMOAT-1 vesicles in
the absence of ATP. The uptake was linear with incubation
Fig. 1. Expression of human cMOAT in human cMOAT cDNA-
transfected CHO-K1 and LLC-PK1 cells by Western blot analysis.
Fig. 2. Immunolocalization of human cMOAT in human cMOAT
cDNA-transfected CHO-K1 and LLC-PK1 monolayers by confocal
laser scanning microscopy. The panels of CHO/CMV (A), CHO/
cMOAT-1 (B) and CHO/cMOAT-2 (C) show horizontal sections of
the cell layers. The panels of LLC/CMV (D), LLC/cMOAT-1(E),
LLC/cMOAT-2 (F) show the top views of the monolayers. The ver-
tical section (G) of the cell layer indicated by arrow in panel F
shows appearance of human cMOAT in the apical plasma mem-
brane. The positions of apical and basal plasma membrane are indi-
cated on the right of panel G. Bar = 25 Wm.
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time for 2 min (Fig. 3A). To con¢rm that [3H]LTC4 uptake
re£ects the transport of substrate into the vesicle lumen rather
than the surface or intramembrane binding, we analyzed the
osmotic sensitivity of [3H]LTC4 uptake. High osmotic pres-
sure reduces the intravesicular space by shrinking the mem-
brane vesicles, resulting in reduced uptake capacity. Osmotic
sensitivity was examined by analyzing ATP-dependent
[3H]LTC4 uptake by CHO/cMOAT-1 vesicles incubated in
various concentrations of sucrose. The amounts of [3H]LTC4
accumulated in CHO/cMOAT-1 vesicles decreased propor-
tionally to the increasing osmolarity of the extravesicular me-
dium, indicating that a signi¢cant amount of [3H]LTC4 was
actually transported into the intravesicular lumen of the
CHO/cMOAT-1 vesicles (Fig. 3B). We further examined the
ATP concentration dependence of [3H]LTC4 uptake. Line-
weaver-Burk analysis indicated that [3H]LTC4 uptake was
saturable with respect to ATP concentration. Kinetic analysis
revealed that the Km value for ATP in CHO/cMOAT-1
vesicles was 175 WM (Fig. 3C). The LTC4 concentration de-
pendence of [3H]LTC4 uptake was analyzed. Lineweaver-Burk
analysis indicated that [3H]LTC4 uptake was saturable with
respect to LTC4 concentration. Kinetic analysis revealed that
the Km value for LTC4 in CHO/cMOAT-1 vesicles was 0.24
WM (Fig. 3D).
We examined if the drug sensitivity to vincristine, cisplatin
and etoposide is altered in human cMOAT cDNA transfec-
tants. Dose-response curves were assayed by colony formation
assay in the presence of various doses of each drug. CHO/
cMOAT-1, 2 cells showed about 2-fold higher resistance to
vincristine and to cisplatin, respectively (Fig. 4A and B) than
CHO/CMV cells. LLC/cMOAT-1, 2 cells showed about 7-fold
higher resistance to vincristine (Fig. 4D) and about 2-fold
higher resistance to cisplatin (Fig. 4E) than LLC/CMV cells.
However, no change appeared in the drug sensitivity to etopo-
side between empty vector transfectants and human cMOAT
cDNA transfectants (Fig. 4C and F).
We examined if human cMOAT changes cellular accumu-
lation of vincristine, cisplatin and etoposide. Cellular accumu-
lation of [3H]vincristine in both human cMOAT cDNA-trans-
fected CHO-K1 (Fig. 5A) and LLC-PK1 (Fig. 5B) cells
decreased greatly compared with empty vector transfectants.
Cellular accumulation of cisplatin in both human cMOAT
cDNA transfectants also decreased signi¢cantly compared
with empty vector transfectants. The decreased cellular levels
of [3H]vincristine and cisplatin in both human cMOAT cDNA
transfectants were about 50% and 80%, respectively, com-
pared with those in empty vector transfectants. However, no
Fig. 3. Transport studies of [3H]LTC4 by membrane vesicles. A:
Time course of [3H]LTC4 accumulation in membrane vesicles from
CHO/CMV and CHO/cMOAT-1 cells in the presence or absence of
4 mM ATP. CHO/CMV3ATP (E), CHO/CMV+ATP (F), CHO/
cMOAT-13ATP (a) and CHO/cMOAT-1+ATP (b). B: E¡ect of
osmolarity on the ATP-dependent [3H]LTC4 accumulation in mem-
brane vesicles from CHO/cMOAT-1 cells (b). The [3H]LTC4 accu-
mulation was measured at increasing concentrations of sucrose
(0.25^1 M) in the presence or absence of 4 mM ATP for 2 min. C:
E¡ect of ATP concentration on the rate of [3H]LTC4 uptake in
membrane vesicles from CHO/cMOAT-1 cells (b). The [3H]LTC4
uptake was measured at various concentrations of ATP for 2 min.
D: E¡ect of LTC4 concentration on the rate of [3H]LTC4 uptake in
membrane vesicles. Membrane vesicles (25 Wg of protein) from
CHO/cMOAT-1 cells (b) were incubated at various concentrations
of LTC4 in the presence or absence of 4 mM ATP for 2 min. A, C,
D: Each point represents the average of two separate experiments.
B: Each point represents the average of three separate experiments;
bars, S.E.
Fig. 4. Comparison of dose-response curves to vincristine (1^350 ng/
ml), cisplatin (1^1500 ng/ml) and etoposide (10^2000 ng/ml) in hu-
man cMOAT cDNA transfectants and empty vector transfectants in
CHO-K1 (A, B, C) and LLC-PK1 (D, E, F) cells. IC50 values (ng/
ml) for vincristine were 78 þ 7 (CHO/CMV) and 9 þ 1 (LLC/CMV);
those for cisplatin were 425 þ 5 (CHO/CMV) and 62 þ 4 (LLC/
CMV); and those for etoposide were 580 þ 8 (CHO/CMV) and
880 þ 10 (LLC/CMV). IC50 values were almost the same between
empty vector transfectants and parental cells (data not shown). Vin-
cristine (A, D); cisplatin (B, E); and etoposide (C, F). CHO/CMV
and LLC/CMV (a), CHO/cMOAT-1 and LLC/cMOAT-1 (b),
CHO/cMOAT-2 and LLC/cMOAT-2 (F). 100% corresponds to the
number of colonies in the absence of any drug. Each point indicates
the average of three separate experiments; bars, S.D.
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change appeared in the cellular accumulation of [3H]etoposide
between empty vector transfectants and human cMOAT
cDNA transfectants (Fig. 5A and B).
Loe et al. [13] have reported that exogenous addition of
vincristine and vinblastine which are substrates for MRP1
inhibit the MRP1 mediated ATP-dependent transport of
LTC4, and that the inhibition is signi¢cantly enhanced by
physiological concentration of GSH. We then examined if
human cMOAT modulates the membrane transport of anti-
cancer agents in association with GSH. We examined the
e¡ect of exogenous addition of vincristine, cisplatin and eto-
poside on the human cMOAT mediated ATP-dependent
LTC4 uptake in the absence (Fig. 6A) or presence (Fig. 6B)
of 3 mM GSH. The administration of vincristine and cisplatin
at 100 WM signi¢cantly blocked the ATP-dependent uptake of
LTC4 in the absence or presence of GSH. The administration
of vincristine and cisplatin at 10 WM also signi¢cantly
(P6 0.05) blocked the ATP-dependent uptake of LTC4 in
the presence of GSH (Fig. 6B). In contrast, there appeared
no such inhibition of the ATP-dependent uptake of LTC4 by
exogenous addition of etoposide at 10 and 100 WM even in the
presence of GSH.
4. Discussion
In this study we isolated transfected cell lines expressing
human cMOAT predominantly on the plasma membrane.
The size of the transfected human cMOAT protein is smaller
than the endogenous human cMOAT protein in HepG2 cells.
This di¡erence may correspond to a di¡erent extent of glyco-
sylation because of a species di¡erence.
Our study revealed that human cMOAT had a high a⁄nity
Km value of 0.24 WM for LTC4. Human MRP1 also trans-
ports LTC4 and had Km values of 0.035 WM to 0.105 WM for
LTC4 [9,11,12,21]. The Km values for LTC4 of human
cMOAT appear to be about 2-fold to 7-fold higher than those
of human MRP1. Rat cMOAT shows Km values of 0.25^0.32
WM for LTC4 [22,23], which appear to be comparable to that
of human cMOAT. Thus, the transport of LTC4 was also
modulated by human cMOAT like as MRP1.
This study indicated that human cMOAT cDNA transfec-
tants showed about 2-fold to 7-fold higher resistance to vin-
cristine and about 2-fold higher resistance to cisplatin, but a
similar sensitivity to etoposide compared with empty vector
transfectants. The growth rate is the same between human
cMOAT cDNA transfectants and empty vector transfectants
(data not shown) and is not likely contributing to the change
of resistance observed. In this study we also observed that
cellular accumulation of vincristine and cisplatin in human
cMOAT cDNA transfectants decreased, but not of etoposide.
Moreover, the cMOAT mediated ATP-dependent LTC4 up-
take by membrane vesicles was inhibited by exogenous addi-
tion of vincristine and cisplatin, but not that of etoposide.
Although human cMOAT is reported not to be expressed
on plasma membrane in non-polarized cells transfected with
human cMOAT cDNA [16], our data clearly show that hu-
man cMOAT is expressed on plasma membrane in non-po-
larized CHO-K1 as well as polarized LLC-PK1 cells trans-
fected with human cMOAT cDNA. Forced expression of
human cMOAT on plasma membrane is expected to enhance
export of drugs through plasma membrane, resulting in reduc-
tion of cellular level of drugs. These consequences suggest that
vincristine and cisplatin show some a⁄nity to human
cMOAT, and that human cMOAT confers drug resistance
to vincristine and cisplatin by the export of them. Thus, hu-
man cMOAT might be involved in the membrane transport of
some anticancer agents and confer drug resistance similar to
MRP1, but with some di¡erences. Drug sensitivity to vincris-
tine and etoposide is markedly altered, but not for cisplatin in
MRP1 cDNA-transfected cells or mrp(3/3) cell line [3,4,24].
The transport of etoposide might be rather speci¢cally medi-
ated through MRP1 than through human cMOAT. During
the preparation of this report, Cui et al. have reported that
forced expression of human cMOAT confers drug resistance
to cisplatin and vincristine [25], consistent with our present
study. However, their human cMOAT cDNA transfectants
are also resistant to etoposide [25]. It remains unclear why
drug sensitivity to etoposide is altered in their human cMOAT
cDNA transfectants, unlike ours. Further study should be
required to examine if any di¡erence in experimental assay
system, cell lines employed, and also cellular distribution of
human cMOAT is responsible for the discrepancy.
Fig. 5. Comparison of cellular accumulation of [3H]etoposide,
[3H]vincristine, and cisplatin in CHO/cMOAT transfectants (A) and
LLC/cMOAT transfectants (B). A: CHO/CMV (E), CHO/cMOAT-1
(gray box) and CHO/cMOAT-2 (F) cells. B: LLC/CMV (E), LLC/
cMOAT-1 (gray box) and LLC/cMOAT-2 (F) cells. All results were
normalized to cellular protein. 100% corresponds to the accumu-
lation of each drug in each empty vector transfectant. Each value
represents the average of three separate experiments; bars, S.D.
*, P6 0.01 compared with CHO/CMV cells or LLC/CMV cells.
Fig. 6. E¡ect of vincristine, cisplatin and etoposide on ATP-depend-
ent [3H]LTC4 uptake in the absence (A) or presence (B) of 3 mM
GSH. Membrane vesicles from CHO/cMOAT-1 cells were incubated
with three di¡erent anticancer agents at 10 or 100 WM for 2 min.
Control (E) ; etoposide (10 WM) (light dashed box); etoposide (100
WM) (dark dashed box); vincristine (10 WM) (light gray box); vin-
cristine (100 WM); cisplatin (10 WM) (dark gray box); cisplatin (100
WM) (F). 100% corresponds to ATP-dependent [3H]LTC4 uptake in
each control. Bars represent means ( þ S.D.) of triplicate determina-
tions. *, P6 0.05 compared with control. **, P6 0.01 compared
with control.
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The human cMOAT mediated LTC4 uptake by membrane
vesicles was more greatly inhibited by each vincristine or cis-
platin in the presence of GSH than in the absence of GSH.
Loe et al. [12] have reported that GSH signi¢cantly enhances
the ability of vincristine and vinblastine to inhibit MRP1
mediated ATP-dependent transport of LTC4, suggesting that
either e¥ux of certain drugs requires activation of MRP1 by
GSH or a co-transport mechanism with GSH is involved in
the MRP1-dependent drug transport [26]. Such co-transport
mechanism might be also partly operated in the human
cMOAT-dependent transport of vincristine or cisplatin with
GSH.
In conclusion, human cMOAT, a family of MRP, shows a
high a⁄nity to LTC4 like MRP1. Drug resistance to vincris-
tine or cisplatin appears to be modulated by human cMOAT
through transport of the agents, possibly in direct or indirect
association with GSH.
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